The FDA just approved a first-of-its-kind Alzheimer's treatment. But is it effective?


Despite questions surrounding its efficacy, the Food and Drug Administration on Monday approved a groundbreaking new medication that attacks the underlying Alzheimer's disease process rather than treating just its symptoms, writes The New York Times. It is the first drug of its kind, and the first new Alzheimer's treatment in 18 years.
Aducanumab, the drug developed by biotech company Biogen and Japanese pharmaceutical company Eisai, reduces levels of amyloid, an Alzheimer's biomarker and protein that "clumps into plaques" in a patient's brain, the Times writes. However, experts and doctors remain divided over whether this will have a substantial-enough effect to warrant approval, particularly as amyloid protein reduction may help only patients early in their disease progression, Time reports. On top of that concern, clinical trials also saw instances of brain swelling or bleeding, leading others to wonder if the risks outweigh the benefits, writes the Times.
Critics cite two conflicting aducanumab clinical trials in explaining their hesitation — one study showed positive cognitive effects, and the other reportedly showed none at all. Biogen later claimed its "initial read of the data was incomplete," Time writes, and the FDA will now require the manufacturer to conduct another, post-approval trial to verify its claims. The infusion-based treatment will still be available to patients in the meantime, per the Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Even with outstanding questions about aducanumab's "modest" clinical effect, supporters view the drug's approval as a win in the fight against an incredibly debilitating disease, says Time. "What we are trying to do is to delay the disabling phases of the disease and preserve quality of life," said Dr. Stephen Salloway, one of the principal investigators for the aducanumab trials, "Although the data has issues, this drug offers some chance of doing that."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.
-
Do smartphone bans in schools work?
The Explainer Trials in UK, New Zealand, France and the US found prohibition may be only part of the solution
-
Doom: The Dark Ages – an 'exhilarating' prequel
The Week Recommends Legendary shooter adds new combat options from timed parries to melee attacks and a 'particularly satisfying' shield charge
-
7 US cities to explore on a microtrip
The Week Recommends Not enough vacation days? No problem.
-
Sea lion proves animals can keep a beat
speed read A sea lion named Ronan beat a group of college students in a rhythmic dance-off, says new study
-
Humans heal much slower than other mammals
Speed Read Slower healing may have been an evolutionary trade-off when we shed fur for sweat glands
-
Novel 'bone collector' caterpillar wears its prey
Speed Read Hawaiian scientists discover a carnivorous caterpillar that decorates its shell with the body parts of dead insects
-
Scientists find hint of alien life on distant world
Speed Read NASA's James Webb Space Telescope has detected a possible signature of life on planet K2-18b
-
Katy Perry, Gayle King visit space on Bezos rocket
Speed Read Six well-known women went into lower orbit for 11 minutes
-
Scientists map miles of wiring in mouse brain
Speed Read Researchers have created the 'largest and most detailed wiring diagram of a mammalian brain to date,' said Nature
-
Scientists genetically revive extinct 'dire wolves'
Speed Read A 'de-extinction' company has revived the species made popular by HBO's 'Game of Thrones'
-
Dark energy may not doom the universe, data suggests
Speed Read The dark energy pushing the universe apart appears to be weakening